Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006

Ann Oncol. 2008 Mar;19(3):481-6. doi: 10.1093/annonc/mdm486. Epub 2007 Nov 20.

Abstract

Background: Although disease-free survival (DFS) is accepted as a valid end point in adjuvant breast cancer trials, improvement in 2-year DFS has never been formally established as an adequate correlate for 5-year overall survival (OS). We set out to ascertain if changes in 2-year DFS can be used to accurately predict 5-year OS changes.

Design: We conducted a systematic Medline search (1966-2006) for randomized adjuvant breast cancer trials of >100 patients per arm with 2-year DFS and 5-year OS data. A univariate regression model weighted by trial sample size was constructed to determine whether 2-year DFS differences between treatment arms within trials were predictive of 5-year OS differences.

Results: A total of 126 studies containing 149 treatment comparisons met the inclusion criteria. Difference in 2-year DFS was a significant predictor of difference in 5-year OS. For every 1% increase in 2-year DFS difference, the 5-year OS difference increased by 0.5%-0.55%. The proportion of variation explained ranged from 0.38 to 0.42, with a wide prediction interval.

Conclusion: There is a statistically significant correlation, of moderate strength, between difference in 2-year DFS between treatment comparisons and difference in 5-year OS but the correlation is not strong enough to be used as a predictor.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Breast Neoplasms / mortality*
  • Breast Neoplasms / therapy*
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphatic Metastasis
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasms, Second Primary / epidemiology
  • Survival Rate